MaxCyte's trading update and recent news flow show how its electroporation technology is a key enabler for many cell therapies. There are over 35 cell therapies in development that use MaxCyte's devices, and recent papers show its potential use in CRISPR cell therapies. MaxCyte's own therapeutic programme, CARMA, should enter the clinic in H117, and a new collaboration expands its CAR platform into haematological cancers. Scientific progress has been matched on the financial front, with sales growing by over 30% in FY16, for a second consecutive year. We raise our valuation per share by 64p to 253p.
24 Jan 2017
Advancing impressively on all fronts
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Advancing impressively on all fronts
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
24 Jan 2017 -
Author:
Mick Cooper PhD -
Pages:
6
MaxCyte's trading update and recent news flow show how its electroporation technology is a key enabler for many cell therapies. There are over 35 cell therapies in development that use MaxCyte's devices, and recent papers show its potential use in CRISPR cell therapies. MaxCyte's own therapeutic programme, CARMA, should enter the clinic in H117, and a new collaboration expands its CAR platform into haematological cancers. Scientific progress has been matched on the financial front, with sales growing by over 30% in FY16, for a second consecutive year. We raise our valuation per share by 64p to 253p.